- Details
- Amy Luckenbaugh joins Sam Chang to discuss highlights from SUO 2024, focusing on two significant late-breaking trials in non-muscle invasive bladder cancer. She examines a study combining intravesical gemcitabine with BCG for BCG-exposed patients, which shows promising complete response rates, and reviews results from a phase III trial of cretostimogene in BCG-unresponsive disease with carcinoma i...
|
- Details
- Jean Hoffman-Censits joins Sam Chang to discuss adjuvant systemic therapy approaches in urothelial carcinoma. She examines results from key studies of nivolumab, pembrolizumab, and atezolizumab in the adjuvant setting, highlighting the positive outcomes of the first two agents while exploring why the atezolizumab trial proved negative. The discussion emphasizes the importance of circulating tumor...
|
- Details
- Jacob Taylor joins Ashish Kamat to discuss a multicenter study comparing long-term outcomes between bladder-sparing therapies and upfront radical cystectomy in BCG-unresponsive bladder cancer. Drawing from data across ten institutions in the US, Canada, and France, Dr. Taylor presents findings showing no significant difference in overall survival between the two approaches, though patients undergo...
|
- Details
- Richard Matulewicz discusses implementing smoking cessation in urologic oncology practice. The discussion highlights smoking cessation as a powerful intervention that can increase overall survival by nearly two years in cancer patients. Matulewicz emphasizes that while urologists frequently encounter tobacco-related diseases, with approximately 1.3 million visits annually involving smokers, there...
|
- Details
- Yair Lotan discusses a multicenter study examining the impact of tumor stage on outcomes in BCG-unresponsive bladder cancer patients undergoing bladder-sparing therapies. Analyzing data from 401 patients across 10 centers, the research demonstrates that patients with T1 disease have significantly worse outcomes in terms of progression, metastasis, and cancer-specific survival compared to those wit...
|
- Details
- Yair Lotan joins Ashish Kamat to discuss a multicenter retrospective study comparing sequential intravesical gemcitabine and docetaxel (gem/doce) with BCG in BCG-unresponsive non-muscle invasive bladder cancer. The research examines outcomes in 299 patients over a 20-year period, finding that gem/doce is associated with improved progression-free survival, cancer-specific survival, and lower rates...
|
- Details
- Gopa Iyer joins Sam Chang to discuss FGFR3 inhibition in urothelial cancer. The discussion explores how FGFR3 alterations are more prevalent in low-grade and early-stage bladder cancer, with current treatment options centered on erdafitinib, the only FDA-approved targeted therapy for FGFR3-altered advanced disease. While erdafitinib shows efficacy, its systemic toxicity presents challenges, partic...
|
- Details
- David D'Andrea joins Ashish Kamat to discuss a systematic review and cost-effectiveness analysis of treatment options for patients who fail BCG therapy in non-muscle-invasive bladder cancer. The study compares radical cystectomy with newer FDA-approved drugs, analyzing both costs and quality of life outcomes over a two-year period. Using Markov modeling, the research examines treatments including...
|
- Details
- Hadley Wyre discusses the prevention and management of long-term complications following radical cystectomy, focusing particularly on ureteroenteric anastomotic strictures and parastomal hernias. Dr. Wyre emphasizes key surgical principles for preventing strictures, including the benefits of extensive ureteral spatulation and a no-touch technique, while recommending against endoscopic treatments i...
|
- Details
- Sam Chang hosts a discussion with Gal Wald and Eugene Pietzak about intravesical gemcitabine and BCG combination therapy for BCG-exposed non-muscle-invasive bladder cancer. The phase II trial demonstrates promising results with a 94% complete response rate at six months and 81% at twelve months using an alternating schedule of gemcitabine and BCG over ten weeks. The treatment shows a favorable tox...
|
